Pharmacokinetics of Venetoclax, a Novel BCL-2 Inhibitor, in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Non-Hodgkin Lymphoma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Pharmacokinetics of Venetoclax, a Novel BCL-2 Inhibitor, in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Non-Hodgkin Lymphoma

Published:2016-11-15 Issue:4 Volume:57 Page:484-492
ISSN:0091-2700
Container-title:The Journal of Clinical Pharmacology
language:en
Short-container-title:The Journal of Clinical Pharmacology

Author:

Salem Ahmed Hamed¹²,Agarwal Suresh K.¹,Dunbar Martin¹,Enschede Sari L. Heitner³,Humerickhouse Rod A.⁴,Wong Shekman L.¹

Affiliation:

1. Clinical Pharmacology and Pharmacometrics; AbbVie Inc; North Chicago IL, USA

2. Clinical Pharmacy; Faculty of Pharmacy; Ain Shams University; Cairo Egypt

3. Global Medical Affairs; AbbVie Inc; North Chicago IL, USA

4. Oncology Development; AbbVie Inc; North Chicago IL, USA

Funder

AbbVie

Genentech

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Reference31 articles.

1. miR-15 and miR-16 induce apoptosis by targeting BCL2;Cimmino;Proc Natl Acad Sci USA,2005

2. Bcl-2 expression in chronic lymphocytic leukemia and its correlation with the induction of apoptosis and clinical outcome;Robertson;Leukemia,1996

3. Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737;Del Gaizo Moore;J Clin Invest,2007

4. Loss in MCL-1 function sensitizes non-Hodgkin's lymphoma cell lines to the BCL-2-selective inhibitor venetoclax (ABT-199);Phillips;Blood Cancer J,2015

5. Selecting efficacious Bcl-2 family inhibitors for optimal clinical outcome;Muqbil;Ann Transl Med,2015

Cited by 105 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Combining the novel FLT3 and MERTK dual inhibitor MRX-2843 with venetoclax results in promising antileukemic activity against FLT3-ITD AML;Leukemia Research;2024-09

2. Venetoclax Induces BCL-2–Dependent Treg to TH17 Plasticity to Enhance the Antitumor Efficacy of Anti–PD-1 Checkpoint Blockade;Cancer Immunology Research;2024-05-23

3. Population Pharmacokinetic Models of Venetoclax in Hematologic Malignancies: A Systematic Review;Drug Design, Development and Therapy;2024-05

4. Clinical pharmacokinetics and pharmacodynamics of venetoclax, a selective B‐cell lymphoma‐2 inhibitor;Clinical and Translational Science;2024-05

5. Venetoclax Clinical Pharmacokinetics After Administration of Crushed, Ground or Whole Tablets;Clinical Therapeutics;2024-05

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3